[The results of the POLONEZ study in Russia]

To define efficacy and safety of enarenal in patients with arterial hypertension (AH).

A total of 235 physicians from 13 towns of Russia and 4291 patients aged 30-70 years with AH of the first-second degree (60% women) participated in the trial. Patients with AH of the second degree were older, more frequently had obesity, diabetes mellitus, hyperlipidemia.

Target blood pressure (TBP) was achieved in 69.5% patients. The target was more frequently achieved in AH of the first degree (87.6%) than of the second (51.4%), in the first degree AH it was achieved with the same frequency in men and women. In AH of the second degree the success with TBP achievement was more frequent in men. Obesity decreased treatment efficacy only in women (TBP was achieved in 88.3% and 79.6% normal and obese women, respectively. Smoking had no effect on the treatment efficacy. In diabetes mellitus systolic blood pressure target (< 140 mm Hg) was seen in 54.2%, < 130 mm Hz--in 28.6%, by diastolic pressure (< 90 mm Hz)--in 88% patients, < 80 mm Hg--in 57%. The response was evaluated according to 5-score scale (from bad to good). The treatment improved the condition of the patients from 2.83 to 3.59 scores after 4 weeks of therapy and to 4.04 after 8 weeks of therapy. Side effects were not registered in 77.6% patients, only 1.9% patients discontinued the drug because of toxicity.

Enarenal, generic of enalapril, demonstrated efficacy comparable to that of the other ACE inhibitors, good tolerance and is recommended for treatment of hypertension.